Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1993-1-13
|
pubmed:abstractText |
In our previous study 1), 2), 3) we reported the changes of coagulation-fibrinolysis, kallikrein-kinin system and kininase in preclampsis. In this study, we tried to obtain systemic information of chronic DIC status with regard to kallikrein-kinin system in severe preeclampsia. This systemic information was evaluated in 20 cases of normal gravidas from 28 to 42 weeks of gestation as a control by measuring plasma Thrombin/Antithrombin III complex (TAT), tissue plasminogen activator (tPA) plasminogen activator inhibitor (PAI) complex, active plasminogen inhibitor-1 (active PAI), 2PI plasmin complex (PIC). Results: The levels of plasma TAT and tPA significantly increased (TAT = 10.9 +/- 8.3 ng/ml n = 24 M +/- SD P < 0.02, tPA = 6.1 +/- 3.2 ng/ml n = 10 M +/- SD P < 0.01), tPA PAI C and active PAI markedly increased (tPA PAI C = 85.07 +/- 50.01 ng/ml n = 24 P < 0.05, active PAI = 407.4 +/- 166.0 ng/ml n = 24 P < 0.205), and PIC and D-dimer = 435.1 +/- 145.2 ng/ml n = 8 M +/- SD P < 0.001) in severe preeclampsia as compared with those of normal values (TAT = 6.1 2.0 ng/ml, tPA = 3.6 +/- 1.5 ng/ml, tPA PAI C = 57.9 +/- 30.8 ng/ml, active PAI = 304.2 +/- 148.6 ng/ml, PIC = 0.49 +/- 0.24 mg/ml, D-dimer = 282.9 +/- 75.3 ng/ml).(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antithrombin III,
http://linkedlifedata.com/resource/pubmed/chemical/Fibrinolysin,
http://linkedlifedata.com/resource/pubmed/chemical/Kallikreins,
http://linkedlifedata.com/resource/pubmed/chemical/Kinins,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Hydrolases,
http://linkedlifedata.com/resource/pubmed/chemical/Plasminogen Activator Inhibitor 1,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Plasminogen Activator,
http://linkedlifedata.com/resource/pubmed/chemical/antithrombin III-protease complex
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0379-0363
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
38 ( Pt 2)
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
342-9
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:1462840-Antithrombin III,
pubmed-meshheading:1462840-Blood Coagulation,
pubmed-meshheading:1462840-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:1462840-Female,
pubmed-meshheading:1462840-Fibrinolysin,
pubmed-meshheading:1462840-Fibrinolysis,
pubmed-meshheading:1462840-Humans,
pubmed-meshheading:1462840-Kallikreins,
pubmed-meshheading:1462840-Kinins,
pubmed-meshheading:1462840-Peptide Hydrolases,
pubmed-meshheading:1462840-Plasminogen Activator Inhibitor 1,
pubmed-meshheading:1462840-Pre-Eclampsia,
pubmed-meshheading:1462840-Pregnancy,
pubmed-meshheading:1462840-Pregnancy Trimester, Third,
pubmed-meshheading:1462840-Reference Values,
pubmed-meshheading:1462840-Tissue Plasminogen Activator
|
pubmed:year |
1992
|
pubmed:articleTitle |
Studies of blood coagulation-fibrinolysis regarding kallikrein-kinin system in severe preeclampsia.
|
pubmed:affiliation |
Division of Perinatal and Maternal Medicine, Akita University School of Medicine, Japan.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|